SCHEMBL6860923

SCHEMBL6860923

Cc1cc([C@H](N)C(=O)O)cc(C)c1Oc1ccc2[nH]cc(S(=O)(=O)c3ccc(C(F)(F)F)cc3)c2c1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 2/20 0.47
THRA P10827 6/20 0.40
THRB P10828 6/20 0.40
SMN1; SMN2 Q16637 4/20 0.40
HTT P42858 3/20 0.40
LMNA P02545 2/20 0.40
TP53 P04637 1/20 0.39
KDM4E B2RXH2 2/20 0.39
MEN1 O00255 4/20 0.38
KMT2A Q03164 4/20 0.38
RXFP1 Q9HBX9 1/20 0.38
POLB P06746 1/20 0.36
TDP1 Q9NUW8 1/20 0.36
TRPV1 Q8NER1 1/20 0.36
BACE1 P56817 1/20 0.35
AKR1B1 P15121 1/20 0.35
PTGDR2 Q9Y5Y4 1/20 0.35
HDAC3 O15379 1/20 0.35
HDAC4 P56524 1/20 0.35
HDAC1 Q13547 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6860860 1.00 MAPT (0.47) MAPTTHRATHRBSMN1; SMN2HTT
SCHEMBL6516023 0.91 THRA (0.46) MAPTTHRATHRBSMN1; SMN2HTT
SCHEMBL6515697 0.91 THRA (0.46) MAPTTHRATHRBSMN1; SMN2HTT
SCHEMBL6514162 0.90 MAPT (0.42) MAPTTHRATHRBSMN1; SMN2HTT
SCHEMBL6859301 0.90 MAPT (0.42) MAPTTHRATHRBSMN1; SMN2HTT
SCHEMBL6520545 0.90 MAPT (0.42) MAPTTHRATHRBSMN1; SMN2HTT
SCHEMBL6519217 0.90 SMN1; SMN2 (0.51) MAPTTHRATHRBSMN1; SMN2HTT
SCHEMBL6512209 0.90 SMN1; SMN2 (0.51) MAPTTHRATHRBSMN1; SMN2HTT
SCHEMBL6519222 0.90 SMN1; SMN2 (0.51) MAPTTHRATHRBSMN1; SMN2HTT
SCHEMBL6513233 0.90 MAPT (0.59) MAPTTHRATHRBSMN1; SMN2HTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6794406-B2 FOR THERAPY AND PROPHYLAXIS OF ARTERIOSCLEROSIS AND HYPERCHOLESTEROLAEMIA BAYER AKTIENGESELLSCHAFT (DE) 2004-09-21 US disclosed
US-20030078288-A1 Indole derivatives BAYER AKTIENGESELLSCHAFT (DE) 2003-04-24 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030078288-A1 Indole derivatives IDO1, IDO2, TPH2 MAPT 839/4885THRA 2460/4885THRB 1772/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.